NRIX
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Article Summary
HOLD- Nurix Therapeutics Inc. (Nasdaq: NRIX) announced closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg following expiration of waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion, with development costs shared 40% by Nurix and 60% by Roche.
- The parties will equally split the profits and losses from U.S. commercialization, with Nurix receiving royalties ranging from the low- to high-teens, while Roche will be responsible for commercialization outside of the United States.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -58.4% | 25% | 0.0 ptsDeclining (-58.4%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 33.8% | 25% | 90.0 ptsExcellent (33.8%) - Strong outlook |
| Target Price Upside ? | 43.0% | 20% | 95.0 ptsHuge Upside (43.0%) - Target: $33.57 vs Current: $23.48 |
| Gross Margin % ? | 53.1% | 15% | 80.0 ptsVery Healthy (53.1%) - High-quality margins |
| Drawdown from 52-Wk High ? | -6.4% | 15% | 20.0 ptsBarely a Dip (-6.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NRIX
- Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
- The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
- It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
- The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.
- The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
- Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.